Home · Health · Sep 3 archive
Ionis Wins FDA Approval for Alexander Disease Drug
Developing
In Short: The FDA has approved Zanvastro for treating Alexander disease, a rare neurological disorder, based on stable walking speed in treated patients compared to a 33% decline in the control group.
The FDA has approved Zanvastro, a drug developed by Ionis, for the treatment of Alexander disease, a rare and deadly neurological disorder. This approval is based on a pivotal trial where walking speed, a key measure of motor function, remained stable in treated patients, while those in the control group experienced a 33% decline.
Researchers noted that the drug was generally safe, with serious adverse events more frequently occurring in the control group. This approval marks a significant breakthrough for patients suffering from this rare condition, offering a potential stabilization in their motor function.
Alexander disease is a rare and progressive disorder that primarily affects the brain and spinal cord, leading to severe neurological symptoms and often resulting in early death. The approval of Zanvastro provides a new treatment option for managing the disease's impact on patients' motor skills.
What's confirmed
What's still developing
- The FDA approved the drug, Zanvastro, for use in children and adults after a pivotal trial showed that walking speed, a common measure of motor function in neurologic disease, stayed stable in treated patients while…
- Researchers found that the drug was generally safe, with serious adverse events more common in the control group than among those treated.
Sources
- STATlink